Table 1 Baseline characteristics of the studies in the meta-analysis
From: Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis
Study (Reference) | Year | Country | Treatment | Sample size(Male, n) | Mean/median Ages(years) | Tumor vascular invasion (yes) | NLR (cut-off used;n) |
|---|---|---|---|---|---|---|---|
Halazun[38] | 2009 | USA | LT | 150(119) | 57.1 | 45 | 5 |
Motomura[30] | 2013 | Japan | LT | 158(92) | 57 | 59 | 4 |
Bertuzzo[36] | 2011 | Italy | LT | 219(186) | 57 | 124 | 5 |
Limaye[27] | 2013 | USA | LT | 160(130) | 55.5/55.1 | 25 | 5 |
Wang[34] | 2011 | China | LT | 101(92) | 48.4 | 30 | 3 |
Gomez[39] | 2008 | UK | SR | 96(72) | 65 | 49 | 5 |
Mano[24] | 2013 | Japan | SR | 958(689) | 67 | NA | 2.81 |
McNally[29] | 2013 | USA | TACE | 103(77) | 56 | NA | 5 |
Huang[37] | 2011 | China | TACE | 145(134) | 49 | 39 | 3.3 |
Pinato1[33] | 2012 | UK | TACE | 54(40) | 63 | NA | 5 |
Chen[35] | 2011 | Taiwan | RF | 192(95) | 65.7 | NA | 2.4 |
Dan[25] | 2013 | China | RF | 178(159) | 57 | NA | 1.9 |
Oh[26] | 2013 | Korea | Mix | 318((240) | 58 | 107 | 2.3 |
Pinato2[32] | 2012 | UK | Mix | 112(90) | 65 | NA | 5 |
Kinoshita[31] | 2012 | Japan | Mix | 150(106) | 72 | NA | 5 |
Study | Sampling time | Follow-up Mean/median (months) | Outcome measured | Multivariate analysis | Patients with elevated NLR | Study quality (Points) | |
Halazun[38] | Pre-LT | 37.2 | DFS/ OS | yes | 13 | 8/9 | |
Motomura[30] | Pre-LT | 40.3 | DFS/OS | yes | 26 | 8/9 | |
Bertuzzo[36] | Pre-LT | 40 | DFS/ OS | yes | 23 | 5/9 | |
Limaye[27] | Pre-LT | 38 | DFS/ OS | yes | 28 | 8/9 | |
Wang[34] | Pre-LT | 34.2 | DFS/ OS | yes | 33 | 7/9 | |
Gomez[39] | Pre-SR | 30 | DFS/ OS | yes | 26 | 6/9 | |
Mano[24] | Pre-SR | NA | DFS/ OS | yes | 238 | 5/9 | |
McNally[29] | Pre-TACE | 11.1 | OS | no | 18 | 7/9 | |
Huang[37] | Pre- TACE | 10 | OS | yes | 59 | 8/9 | |
Pinato1[33] | Pre-TACE | NA | OS | Yes | 9 | 5/9 | |
Chen[35] | Pre-RFA | 34 | OS/DFS | yes | 81 | 7/9 | |
Dan[25] | Pre-RFA | 52.7 | OS/DFS | yes | 91 | 7/9 | |
Oh[26] | Pre-treatment | 13.9 | OS | yes | 189 | 7/9 | |
Pinato2[32] | Pre-treatment | 10 | OS | yes | 25 | 7/9 | |
Kinoshita[31] | Pre-treatment | 18 | 0S | no | 15 | 6/9 | |